ATE371372T1 - Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren - Google Patents

Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren

Info

Publication number
ATE371372T1
ATE371372T1 AT98949797T AT98949797T ATE371372T1 AT E371372 T1 ATE371372 T1 AT E371372T1 AT 98949797 T AT98949797 T AT 98949797T AT 98949797 T AT98949797 T AT 98949797T AT E371372 T1 ATE371372 T1 AT E371372T1
Authority
AT
Austria
Prior art keywords
viruses
neoplasms
treatment
interferon sensitive
clonal viruses
Prior art date
Application number
AT98949797T
Other languages
English (en)
Inventor
Michael Roberts
Robert Lorence
William Groene
Harvey Rabin
Borstel Reid Von
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25487533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE371372(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE371372T1 publication Critical patent/ATE371372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
AT98949797T 1997-10-09 1998-10-09 Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren ATE371372T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94824497A 1997-10-09 1997-10-09

Publications (1)

Publication Number Publication Date
ATE371372T1 true ATE371372T1 (de) 2007-09-15

Family

ID=25487533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949797T ATE371372T1 (de) 1997-10-09 1998-10-09 Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren

Country Status (12)

Country Link
EP (2) EP1905304A3 (de)
JP (3) JP2001519175A (de)
CN (2) CN1281336A (de)
AT (1) ATE371372T1 (de)
AU (1) AU9603898A (de)
CA (1) CA2305269C (de)
DE (1) DE69838340T2 (de)
ES (1) ES2292207T3 (de)
HU (1) HUP0003911A3 (de)
IL (1) IL135507A0 (de)
NZ (4) NZ503664A (de)
WO (1) WO1999018799A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
EP1905304A3 (de) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Behandlung von Neoplasmen mit Viren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU5446700A (en) * 1999-05-28 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
DE19951795A1 (de) * 1999-10-27 2001-05-10 Knebel Doeberitz Magnus Von Verwendung von Parvoviren zur Verbesserung des Allgemeinzustandes bei Tumorpatienten oder Patienten mit chronischen oder konsumierenden Erkrankungen
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
WO2002000233A2 (en) * 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
US20140088177A1 (en) * 2001-07-11 2014-03-27 University Of Miami Recombinant vsv for the treatment of tumor cells
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
NZ536102A (en) * 2002-05-09 2008-01-31 Oncolytics Biotech Inc Oncolytic viruses, in particular reovirus, for reducing pain associated with proliferative disorders, particularly with the growth of a solid tumour mass
EP1944035A1 (de) * 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Verfahren zur Schmerzlinderung durch onkolytische Viren
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
US20050220818A1 (en) * 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004078206A1 (en) 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
EP1933857A2 (de) 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemische behandlung von metastasierten und/oder systemisch dissemierten tumoren mit gm-csf-exprimierenden pockenviren
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
US8512713B2 (en) 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
EP2345415B1 (de) * 2008-09-16 2015-01-21 GenomIdea Inc. Therapeutisches/prophylaktisches mittel gegen prostatakrebs
EP2393921B1 (de) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimäres newcastle disease virus und seine verwendungen
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
EP2327764B1 (de) * 2009-11-30 2011-12-28 United Cancer Research Institute Neuer Klon des Geflügelpestvirus, Herstellung und Anwendung bei der medizinischen Behandlung von Krebs
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2697368B1 (de) 2011-04-15 2019-06-05 Genelux Corporation Klonale stämme von abgeschwächten vaccinia-viren und verwendungsverfahren davon
US20140328798A1 (en) * 2011-11-17 2014-11-06 Deutsches Krebsforschung-Szentrum Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer
US20130129678A1 (en) * 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
SG11201510064WA (en) * 2013-06-14 2016-01-28 Psioxus Theraupeutics Ltd A dosing regime and formulations for type b adenoviruses
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP3837277A4 (de) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai Rekombinante viren der newcastle-krankheit und deren verwendungen zur prävention einer rsv-krankheit oder infektion mit dem menschlichen metapneumovirus
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2699082B1 (fr) * 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
ES2310580T3 (es) * 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
DE69635513T2 (de) * 1995-02-10 2006-08-17 The Regents Of The University Of California, Oakland Menschliche Pancreas Zelllinien: Entwicklungen und Anwendungen
DE69636863T2 (de) * 1995-02-24 2007-11-15 Trustees Of The University Of Pennsylvania Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
EP1905304A3 (de) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Behandlung von Neoplasmen mit Viren

Also Published As

Publication number Publication date
JP2013213058A (ja) 2013-10-17
HK1028935A1 (en) 2001-03-16
NZ553508A (en) 2008-11-28
NZ550147A (en) 2008-09-26
EP1905304A3 (de) 2008-08-13
HUP0003911A2 (hu) 2001-02-28
AU9603898A (en) 1999-05-03
CA2305269A1 (en) 1999-04-22
CN101618049A (zh) 2010-01-06
ES2292207T3 (es) 2008-03-01
WO1999018799A1 (en) 1999-04-22
NZ518945A (en) 2007-03-30
DE69838340T2 (de) 2008-05-21
IL135507A0 (en) 2001-05-20
EP1905304A2 (de) 2008-04-02
EP1032269A1 (de) 2000-09-06
EP1032269A4 (de) 2001-09-19
NZ503664A (en) 2002-08-28
HUP0003911A3 (en) 2007-11-28
JP2009161558A (ja) 2009-07-23
CA2305269C (en) 2012-07-03
EP1032269B1 (de) 2007-08-29
DE69838340D1 (de) 2007-10-11
CN1281336A (zh) 2001-01-24
JP2001519175A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
DE69838340D1 (de) Behandlung von neoplasmen mit interferon-empfindlichen, klonalen viren
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
ATE409043T1 (de) Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von krebs des zentralen nervensystems
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
FI971116L (fi) Fotodynaaminen terapia selektiivisessä solujen inaktivoinnissa veressä sekä immuunijärjestelmän häiriötautien hoito
ATE194608T1 (de) 5-substituierte derivate von mycophenolsäure
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
ATE500830T1 (de) Behandlung von krebs beim menschen mit et743
ATE60329T1 (de) Cumarinderivate, diese enthaltende pharmazeutische zubereitungen und ihre verwendung bei der behandlung von krebs.
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
EP0757697A4 (de) Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
DE58903550D1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples
DE69803303D1 (de) Verwendung von endipalen zur behandlung von schuppenflechte
RU97113660A (ru) Способ лечения детей, больных вторичным панкреатитом
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
IT8985604A0 (it) Cintura con elementi metallici incorporati per trattamento terapeutico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032269

Country of ref document: EP